Profound Medical Corp.
Datakwaliteit: 100%
PROF
Nasdaq
Manufacturing
Measuring & Analyzing Instruments
€ 6,41
▼
€ 0,08
(-1,23%)
Marktkapitalisatie: 232,64 M
Prijs
€ 6,41
Marktkapitalisatie
232,64 M
Dagbereik
€ 6,33 — € 6,54
52-Weeksbereik
€ 3,76 — € 8,95
Volume
20.115
Openen € 6,53
50D / 200D Gem.
€ 6,56
2,22% below
50D / 200D Gem.
€ 6,14
4,38% above
Quick Summary
Belangrijkste Punten
Debt/Equity of 0,14 — conservative balance sheet
Negative free cash flow of -38,38 M
Capital efficient — spends only 1,09% of revenue on capex
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)50,73%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-119,24%
Onder sectorgemiddelde (-51,02%)
ROIC-85,42%
Net Margin-264,44%
Op. Margin-256,27%
Veiligheid
Debt / Equity
0,14
Onder sectorgemiddelde (0,33)
Current Ratio4,18
Interest Coverage-104,71
Waardering
PE (TTM)
-5,46
Onder sectorgemiddelde (-1,98)
P/B Ratio7,24
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (44 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (44 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -5,5 | -2,0 |
| P/B | 7,2 | 5,1 |
| ROE % | -119,2 | -51,0 |
| Net Margin % | -264,4 | -150,2 |
| Rev Growth 5Y % | — | 9,3 |
| D/E | 0,1 | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 50,73% | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 16,10 M | Net Income (TTM) | -42,57 M |
| ROE | -119,24% | ROA | -92,57% |
| Gross Margin | 70,77% | Operating Margin | -256,27% |
| Net Margin | -264,44% | Free Cash Flow (TTM) | -38,38 M |
| ROIC | -85,42% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0,14 | Current Ratio | 4,18 |
| Interest Coverage | -104,71 | Asset Turnover | 0,35 |
| Working Capital | 31,59 M | Tangible Book Value | 32,02 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -5,46 | Forward P/E | N/A |
| P/B Ratio | 7,24 | P/S Ratio | 14,45 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -16,50% | ||
| Market Cap | 232,64 M | Enterprise Value | 212,30 M |
| Per Share | |||
| EPS (Diluted TTM) | 1,41 | Revenue / Share | 0,44 |
| FCF / Share | -1,06 | OCF / Share | -1,05 |
| EPS CAGR (1Y) | 25,89% | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 1,09% | FCF Conversion | 90,16% |
| SBC-Adj. FCF | -43,87 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 |
|---|---|---|
| Revenue | 16,10 M | 10,68 M |
| Net Income | -42,57 M | -27,82 M |
| EPS (Diluted) | 1,41 | 1,12 |
| Gross Profit | 11,39 M | 7,04 M |
| Operating Income | -41,25 M | -33,06 M |
| EBITDA | — | — |
| R&D Expenses | 20,60 M | 16,97 M |
| SG&A Expenses | 32,05 M | 23,13 M |
| D&A | — | — |
| Interest Expense | 394.000,0 | — |
| Income Tax | 252.000,0 | -2.000,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 |
|---|---|---|
| Total Assets | 77,48 M | 70,23 M |
| Total Liabilities | 11,04 M | 9,81 M |
| Shareholders' Equity | 66,43 M | 60,42 M |
| Total Debt | 4,50 M | 4,66 M |
| Cash & Equivalents | 59,72 M | 54,91 M |
| Current Assets | 76,09 M | 69,07 M |
| Current Liabilities | 6,08 M | 6,57 M |
{"event":"ticker_viewed","properties":{"ticker":"PROF","listing_kind":"stock","pathname":"/stocks/prof","exchange":"Nasdaq","country":"US"}}